| Key Takeaways |
| Gastrointestinal symptoms, mainly nausea, vomiting, and diarrhea, are the most common side effects and typically improve within 4 to 8 weeks as the body adjusts. |
| Serious side effects including pancreatitis and thyroid tumors are rare. In a 2-year trial, acute pancreatitis occurred in 0.27 cases per 100 patient years in semaglutide users, versus 0.33 in placebo users. |
| Most people tolerate semaglutide well over time. Only about 4 to 5% of clinical trial participants stopped treatment permanently because of side effects. |
If you have recently started semaglutide, or are weighing your options, understanding what to expect, and what is genuinely rare, makes all the difference.
This guide walks through every major side effect category, backed by clinical trial data, so you can have an informed conversation with your doctor.
1. Why Does Semaglutide Cause Side Effects in the First Place?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a hormone your gut naturally releases after meals.
That hormone signals the brain to reduce appetite, tells the pancreas to release insulin, and slows the rate at which your stomach empties food into the small intestine.
It is that last effect, slowed gastric emptying, that drives the majority of side effects.
When food lingers longer in the stomach, the result can be nausea, a feeling of fullness, and occasional vomiting, especially during the early weeks of treatment or after a dose increase.
The body adapts. For most people, side effects are most noticeable during the dose escalation phase and settle down once a stable maintenance dose is reached. Understanding this timeline helps set realistic expectations.
2. The Most Common Side Effects: What the Data Actually Shows
The STEP clinical trial programme, the pivotal trials that led to FDA approval of Wegovy at 2.4 mg once weekly, provides the most comprehensive side effect data available.
In the STEP 1 trial, 43.9% of semaglutide participants reported nausea, compared with 16.1% on placebo.
Gastrointestinal symptoms as a whole were reported in 82.2% of semaglutide participants in the 2-year STEP 5 trial versus 53.9% on placebo. The important qualifier: the vast majority of these events were rated as mild to moderate in severity.
| Side Effect | Approximate Frequency | Typical Duration |
|---|---|---|
| Nausea | 15% to 44% depending on dose | Peaks at dose increases; usually resolves within 4 to 8 weeks |
| Vomiting | Up to 24% at weight-loss doses | Individual episodes last a median of 2 days |
| Diarrhea | Up to 25% | Individual episodes last a median of 3 days |
| Constipation | Up to 30% | Variable; improves with hydration and fibre intake |
| Abdominal pain / stomach discomfort | Up to 20% | Often tied to dose increases; improves at stable dose |
| Nausea episodes (median duration each) | Common, especially early in treatment | Median of 8 days per episode |
| Headache / dizziness / fatigue | Roughly 10% | Usually transient |
| Decreased appetite | Very common; part of mechanism | Ongoing at therapeutic dose |
Source: Wharton S et al., Diabetes, Obesity and Metabolism, 2021; Garvey WT et al., STEP 5 trial, Nature Medicine, 2022; Novo Nordisk FDA prescribing information, 2025.
A pooled GI tolerability analysis published in Diabetes, Obesity and Metabolism found that nausea episodes had a median duration of just 8 days, diarrhea lasted a median of 3 days, and vomiting 2 days.
Nausea peaked around week 20 during dose escalation and declined steadily afterwards. Only 4.3% of semaglutide participants in the STEP trials permanently stopped treatment because of gastrointestinal side effects.
3. Serious Side Effects: Rare, but Worth Knowing
The following side effects are uncommon. Including them here is not intended to alarm, but to help you recognise warning signs early.
If you experience any of the symptoms below, contact your healthcare provider promptly.
Acute Pancreatitis
Pancreatitis involves inflammation of the pancreas and can cause intense abdominal pain. In a 2-year clinical trial, acute pancreatitis was observed in 0.27 cases per 100 patient years in the semaglutide group and 0.33 cases per 100 patient years in the placebo group.
A 2024 updated meta-analysis published in Endocrinologia, Diabetes y Nutricion examined acute pancreatitis across different semaglutide regimens and concluded that the absolute risk remains low.
That said, if you develop severe abdominal pain that radiates to the back, with or without vomiting, seek medical attention immediately.
People with a history of pancreatitis are generally advised to avoid semaglutide. Discuss this with your prescribing doctor before starting.
Thyroid C-Cell Tumours: Rodent Warning, Human Evidence Nuanced
Semaglutide carries a boxed warning regarding medullary thyroid carcinoma (MTC). This warning comes from studies in rodents that showed increased incidence of thyroid C-cell tumours at sustained high exposure.
Human GLP-1 receptors are expressed differently in thyroid tissue than in rodents, and this finding has not been replicated in humans.
A 2024 systematic literature review in International Journal of Molecular Sciences concluded that current evidence does not establish a causal link between semaglutide use and human thyroid cancer.
However, semaglutide should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Symptoms to watch for: a lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath. Report any of these to your doctor without delay.
Gallbladder Disease
Rapid weight loss of any kind can increase the likelihood of gallstone formation, and semaglutide is no exception.
Cholelithiasis (gallstones) was reported in approximately 1.5% of semaglutide-treated patients in placebo-controlled trials. Symptoms include pain in the upper right abdomen, particularly after meals.
Acute Kidney Injury
Semaglutide itself does not appear to directly damage the kidneys. However, persistent vomiting or diarrhoea can lead to dehydration, which in turn may precipitate acute kidney injury.
Staying well hydrated during treatment is important, especially during periods of gastrointestinal disturbance.
Allergic Reactions
Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 receptor agonists as a class.
These are rare. Symptoms include swelling of the face, lips, tongue, or throat, and difficulty breathing. This constitutes a medical emergency.
Increased Heart Rate
Clinical data show a mean increase in resting heart rate of 2 to 3 beats per minute at the 0.5 mg semaglutide dose. This small increase has not been associated with adverse cardiovascular outcomes; in fact, the large SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in people with overweight or obesity.
4. Injection Site Reactions: What to Expect and How to Minimise Them
According to FDA prescribing information, injection site reactions occurred in 1.4% of Ozempic patients and 2.4% of Wegovy patients in clinical trials. These reactions typically include redness, mild swelling, itching, or brief discomfort at the injection site.
In placebo-controlled trials for Ozempic specifically, injection site discomfort or erythema was reported in only 0.2% of participants, suggesting that these reactions are generally mild and infrequent.
A case report series published in Diabetes Care documented subcutaneous nodule formation at injection sites in a small number of patients, likely caused by repeated injections into the same location.
Tips to Reduce Injection Site Reactions
- Rotate injection sites consistently. Approved sites for Wegovy include the abdomen, front of the thighs, and outer upper arm.
- Allow the pen to come to room temperature before injecting. Cold medication from the refrigerator can increase local discomfort.
- Clean the skin with an alcohol swab and allow it to dry fully before injecting.
- After inserting the needle, hold the dose button for a full 6 seconds before removing the needle.
- Avoid injecting into areas of scar tissue, bruising, or skin irritation.
- Injecting into an area with adequate subcutaneous fat allows for slower, more gradual absorption and less local inflammation.
5. Does Semaglutide Cause Hair Loss? Here Is What the Research Shows
Hair loss is one of the more commonly discussed concerns among semaglutide users, and the evidence here is nuanced.
In the STEP clinical trial programme, alopecia was reported in approximately 3% of participants receiving semaglutide 2.4 mg, compared with approximately 1% on placebo, a statistically meaningful difference.
However, the type of hair loss observed is important. The predominant pattern is telogen effluvium, a temporary, non-scarring form of hair shedding triggered by physiological stress.
Rapid weight loss is a well-established trigger. The mechanism appears to be related to caloric restriction and the body’s stress response to significant weight change, rather than a direct follicle-damaging effect of semaglutide itself.
A 2024 real-world analysis published in the Journal of the American Academy of Dermatology examined data from two large healthcare databases.
The study found that at the lower semaglutide doses of 0.25 to 2 mg weekly, rates of telogen effluvium within six months of starting treatment were 0.80% and 0.83% across the two datasets, considerably lower than the 3% seen at the higher 2.4 mg weight-loss dose.
A 2025 systematic review in PMC noted that among patients who lost more than 20% of body weight, the rate of alopecia was 5.3%, while those losing less than 20% saw a rate of 2.5%. This suggests the degree of weight loss, not simply the drug, is the primary driver.
The reassuring point: hair loss from telogen effluvium is temporary and typically reverses once weight loss stabilises and nutritional intake normalises. Adequate protein intake, generally at least 60 to 80 grams per day for most adults, is the most important protective factor.
6. Semaglutide vs. Liraglutide: How Do the Side Effect Profiles Compare?
Both semaglutide and liraglutide are GLP-1 receptor agonists used for weight management and type 2 diabetes, but they differ in potency, dosing frequency, and side effect intensity.
| Factor | Semaglutide (Ozempic/Wegovy) | Liraglutide (Saxenda/Victoza) |
|---|---|---|
| Dosing frequency | Once weekly (injection) or once daily (Rybelsus oral) | Once daily injection |
| Weight-loss efficacy | Up to ~15% body weight reduction (STEP trials) | Approximately 5% placebo-corrected (clinical trials) |
| GI side effect intensity | Higher; more nausea and vomiting than liraglutide | Lower GI burden; daily lower-peak dosing |
| Unique side effects | Bloating, belching, flatulence, diabetic retinopathy risk in T2D | Increased lipase, fever |
| Cardiovascular benefit | 20% MACE reduction (SELECT trial, 2.4 mg) | Cardiovascular benefit demonstrated (LEADER trial) |
| FDA database adverse events | Higher reporting of eye, skin, and psychiatric events vs liraglutide | Higher GI and infection rates vs semaglutide per FAERS 2025 |
Source: Comparative effectiveness of semaglutide vs liraglutide, Frontiers in Pharmacology, 2025; FAERS database investigation, PMC 2025; STEP 8 trial data.
In head-to-head trial data from the STEP 8 trial, semaglutide produced a mean weight reduction of 9.5% greater than liraglutide over the same period.
The tradeoff is a somewhat higher intensity of gastrointestinal symptoms, particularly during dose escalation. People who are sensitive to nausea or who have pre-existing reflux may find liraglutide’s daily, lower-peak dosing profile easier to tolerate initially.
The choice between agents should always be made with your prescribing physician based on your individual health profile, treatment goals, and tolerance.
7. Rybelsus vs. Injectable Semaglutide: Is the Pill Easier on the Body?
Rybelsus is the oral tablet formulation of semaglutide, approved for type 2 diabetes at doses of 3 mg, 7 mg, and 14 mg. Injectable semaglutide (Ozempic, Wegovy) is used for both type 2 diabetes and chronic weight management, with Wegovy approved up to 2.4 mg weekly.
The key distinction: Rybelsus is approved for diabetes management, not weight loss. Comparing Rybelsus to Wegovy directly is not a like-for-like comparison of the same use case.
Oral semaglutide must be taken on an empty stomach with no more than 120 ml of water, at least 30 minutes before the first food or drink of the day.
Bioavailability from the oral route is approximately 1%, compared with roughly 89% for the subcutaneous injection, which is why the milligram doses differ substantially between formulations.
In clinical studies, oral semaglutide 14 mg daily was noninferior to liraglutide 1.8 mg for HbA1c reduction in type 2 diabetes. The gastrointestinal side effect profile of oral semaglutide is broadly similar to injectable semaglutide, though the peak plasma concentration per dose is lower.
For people with needle anxiety, Rybelsus may feel more accessible, but it requires consistent daily fasting adherence, which can itself be difficult to maintain in a busy daily routine.
8. How Long Do Semaglutide Side Effects Last? A Practical Timeline
Side effect duration depends on where you are in the titration schedule. Injectable semaglutide follows a gradual dose-escalation protocol, typically increasing every four weeks. Oral semaglutide uses 30-day steps.
| Phase | What Most People Experience | Duration |
|---|---|---|
| Weeks 1 to 4 (0.25 mg starter dose) | Mild nausea, possible light-headedness, decreased appetite | Improves as the body adjusts within 1 to 2 weeks |
| Weeks 5 to 16 (dose escalation) | GI symptoms may recur briefly after each dose increase | Each spike typically resolves within 7 to 14 days |
| Week 17 onward (maintenance) | Most GI symptoms substantially reduced or resolved | 67.7% of semaglutide users report no side effects at month 12 |
| Hair loss (if it occurs) | Shedding may begin 2 to 3 months after starting treatment | Typically reverses once weight loss stabilises |
| Injection site reactions | Mild redness or swelling after each injection | Usually resolves within minutes to a few hours |
Source: Novo Nordisk FDA prescribing information; Second Nature real-world data, 2025.
People with pre-existing gastrointestinal conditions, including gastroparesis, irritable bowel syndrome, or gastro-oesophageal reflux disease, may experience a more prolonged side effect. Discuss these conditions with your prescriber before starting treatment.
9. How to Manage Semaglutide Side Effects: Evidence-Based Strategies
The good news is that most semaglutide side effects are manageable with straightforward dietary and lifestyle adjustments.
The following strategies come from clinical recommendations used in the STEP trials and expert consensus guidelines.
For Nausea and Vomiting
- Eat smaller, more frequent meals throughout the day rather than large portions at once.
- Avoid greasy, fried, or very spicy foods during the early weeks of treatment.
- Stay hydrated with small, frequent sips rather than large amounts at once.
- Some people find that taking their injection at bedtime reduces daytime nausea.
- Sit upright for at least 30 minutes after eating.
- If nausea is persistent, speak to your doctor. Short-term anti-nausea medication may be appropriate.
For Constipation
- Increase soluble fibre intake gradually. Fruits, vegetables, legumes, and oats are good sources.
- Aim for at least 8 cups (approximately 2 litres) of fluid daily.
- Light physical movement, such as walking, after meals supports bowel motility.
For Stomach Pain
- Slow down eating and chew thoroughly. Semaglutide slows gastric emptying, so food that moves into the stomach quickly can cause discomfort.
- Keep a simple food diary to identify personal triggers.
- If pain is severe, worsens progressively, or is accompanied by vomiting, contact your doctor. Severe upper abdominal pain is a potential sign of pancreatitis.
For Hair Loss
- Prioritise adequate protein at every meal. Most adults benefit from 60 to 80 grams per day or more.
- Ask your doctor about checking key micronutrient levels including iron, ferritin, zinc, and vitamin D, as deficiencies can amplify hair shedding.
- Avoid very restrictive diets or aggressive caloric deficits while on semaglutide.
- Most hair loss resolves naturally as weight loss stabilises. If shedding persists beyond six months or worsens, seek a dermatology evaluation.
For Injection Site Reactions
- Rotate injection sites rigorously with each dose.
- Allow the pen to warm to room temperature before use.
- A cool compress applied after injection can ease localised discomfort.
10. When Should You Stop Taking Semaglutide?
Most side effects do not require stopping the medication. However, contact your healthcare provider promptly, or seek emergency care, if you experience:
| Symptom | Possible Concern | Action |
|---|---|---|
| Severe, persistent abdominal pain radiating to the back | Potential pancreatitis | Seek emergency care immediately |
| Swelling of face, lips, tongue, or throat; difficulty breathing | Anaphylaxis / severe allergic reaction | Call emergency services immediately |
| Lump or swelling in the neck, hoarseness, trouble swallowing | Possible thyroid concern | Contact your doctor promptly |
| Upper right abdominal pain, especially after meals | Possible gallbladder issue | Contact your doctor |
| Severe diarrhoea or vomiting leading to dehydration | Risk of kidney injury | Contact your doctor; hydrate urgently |
| Vision changes (in people with type 2 diabetes) | Possible diabetic retinopathy | Contact your doctor promptly |
| Persistent suicidal thoughts or significant mood changes | Rare psychiatric risk; monitor closely | Seek mental health support immediately |
Never stop semaglutide abruptly without discussing it with your prescriber first.
If side effects are difficult to manage, your doctor may recommend pausing at your current dose rather than escalating, or temporarily reducing the dose.
| Bottom Line |
| Semaglutide is well-tolerated by the majority of people who take it, but side effects are real and worth understanding. Gastrointestinal symptoms, mainly nausea, vomiting, and stomach discomfort, are the most common. They are also the most manageable, typically improving within four to eight weeks as your body adapts to each dose. |
| Serious side effects are uncommon. Pancreatitis occurred at comparable rates to placebo in a two-year clinical trial. The thyroid tumour warning, while important to know about, is based on rodent data and has not been confirmed in humans. Hair loss, when it occurs, is almost always temporary. |
| Gradual dose escalation, thoughtful dietary changes, and staying alert to red-flag symptoms are the most reliable ways to get the benefits of semaglutide while minimizing discomfort. Speak with your doctor before making any change in the dosage or your diet. |
Frequently Asked Questions
What are all the side effects of semaglutide?
The most common side effects are gastrointestinal: nausea (reported by up to 44% of users at the weight-loss dose), vomiting, diarrhea, constipation, and abdominal discomfort.
Less common effects include headache, fatigue, dizziness, hair shedding, and mild injection site reactions.
Rare but serious effects include acute pancreatitis, gallbladder disease, severe allergic reactions, and acute kidney injury secondary to dehydration. Always review the full prescribing information with your doctor.
Are semaglutide side effects different for injections vs. the pill (Rybelsus)?
The overall side effect profile is similar across formulations, as semaglutide is the same active molecule in both. However, bioavailability differs significantly.
Injectable semaglutide achieves around 89% bioavailability versus approximately 1% for oral Rybelsus, which is why oral doses are measured in milligrams while injectable doses are in fractions of a milligram.
Oral Rybelsus requires strict fasting conditions before each dose. Injection site reactions are exclusive to the subcutaneous forms.
How long do semaglutide side effects typically last?
Gastrointestinal side effects are most pronounced during the dose escalation phase. Individual nausea episodes have a median duration of 8 days, diarrhea 3 days, and vomiting 2 days per episode.
Most people see significant improvement within four to eight weeks of reaching a stable dose. By the twelve-month mark, real-world data show that roughly 67.7% of semaglutide users report no side effects.
Hair shedding, if it occurs, typically peaks two to three months after starting and resolves as weight loss stabilises.
Who should not take semaglutide?
Semaglutide should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
It is also contraindicated in people with known hypersensitivity to semaglutide. Use during pregnancy or breastfeeding is not recommended.
People with a history of pancreatitis should discuss the risk-benefit profile with their prescriber before starting.
Can semaglutide cause stomach pain long term?
Stomach discomfort or pain is primarily associated with the dose escalation phase and typically improves at a stable maintenance dose.
The FDA has received reports of gastroparesis, a condition involving significantly delayed gastric emptying, in some patients on semaglutide and liraglutide.
These are relatively rare, and the FDA has noted it cannot confirm direct causation. If you experience persistent or worsening abdominal pain, particularly pain that radiates to the back, contact your doctor promptly.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, stopping, or modifying any medication or treatment plan.
